Cost-effectiveness of disease-modifying therapy for multiple sclerosis- A population-based study

Neurology®, 07/29/2011

Compared to treating patients with all levels of disease, starting disease–modifying therapies(DMT) earlier was associated with a lower (more favorable) incremental cost–effectiveness ratio compared to initiating treatment at any disease state. Use of DMT in multiple sclerosis(MS) results in health gains that come at a very high cost.

Print Article Summary Cat 2 CME Report